IDT Australia Limited (ASX:IDT)

Market Cap	15.39M -64.2%
Revenue (ttm)	19.00M +1.2%
Net Income	-6.13M
EPS	-0.01
Shares Out	427.43M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	96,184
Open	0.0370
Previous Close	0.0360
Day's Range	0.0370 - 0.0380
52-Week Range	0.0340 - 0.1100
Beta	0.93
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 1, 2026

About IDT Australia

IDT Australia Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API) and finished dose forms (FDF) products in Australia, Asia, Europe, and the United States. The company offers microbiological and analytical testing, clinical packaging, and pharmacy services. It also provides medicinal cannabis and psychedelics; oral finished doses; and aseptic fill and finish solutions for liquid and lyophilised forms. In addition, the company offers mRNA and antibody drug conjugates. Further, the compan...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1975
• Employees: 100
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: IDT

Financial Performance

In fiscal year 2025, IDT Australia's revenue was 19.77 million, an increase of 40.99% compared to the previous year's 14.02 million. Losses were -8.06 million, 49.0% more than in 2024.